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In this issue of Critical Care, Yildiz and colleagues reported the
first randomized, controlled trial on the efficacy and safety of
physiologic doses of steroids in severe sepsis [1]. During the
past 5 years, five phase II trials and a phase III placebo-
controlled trial on cortisol replacement, i.e. prolonged treatment
with physiologic doses of steroids, have been completed in
patients with vasopressor-dependent septic shock (Table 1)
[2–6]. Two of them have already been published in peer-
reviewed journals [2,3], three have been published in abstract
form and will be published shortly in peer reviewed journals
[4–6], and the results of a phase II trial that has just been
completed will be available very soon (Oppert and colleagues,
personal communication). These trials have consistently shown
beneficial effects of cortisol replacement on the amount of
vasopressors [2–6], on the duration of shock [2–4,6], on the
duration and intensity of organ dysfunction [3,6], and on the
intensity of the systemic inflammatory response [5,6]. The
survival benefit observed with cortisol replacement in several
phase II trials [2,4] was recently confirmed by the phase III trial
[6]. In all these trials, cortisol replacement was never associated
with even a trend toward serious side effects. A confirmatory
phase III, multinational, placebo-controlled trial (the CORTICUS
study) is under way, and results should be available within the
next 3 years. In the meantime, given the consistency of the
results across available trials, cortisol replacement should be
considered as a standard of care for patients with vasopressor-
dependent septic shock. Yildiz and colleagues found that, in
patients with severe sepsis, irrespective of the need for
vasopressors, treatment for 10 days with prednisolone given
intravenously twice daily (5 mg at 6 a.m. and 2.5 mg at 6 p.m.)
was associated with a 20% absolute reduction in mortality
within 28 days [1]. These findings are very challenging, because
they suggest that cortisol replacement might be introduced in
severe sepsis as well as in vasopressor-dependent septic
shock, and that the mechanisms underlying the favorable
effects of the treatment might not be limited to a reduction of
the need for vasopressors. Obviously, a phase III trial must be
set up to confirm the potential survival benefit of cortisol
replacement in patients with severe sepsis who are not
vasopressor-dependent.
The study by Yildiz and colleagues addressed another
important issue, i.e. the need for an adrenocorticotropic
hormone (ACTH) test to identify patients with severe sepsis
or septic shock who will benefit from cortisol replacement
[1]. In this small trial, the effects of steroids were not
significantly altered by the results of a short ACTH test.
However, there were only 14 nonresponders (5 in the steroid
group and 9 in the placebo group) to the test, i.e. a cortisol
increment after a 250-µg intravenous bolus of ACTH of less
than 9 µg/dl, as previously defined [7,8]. Subsequently, in
this subset of patients with occult adrenal insufficiency, the
15.6% absolute reduction in 28-day mortality in favor of the
steroid group was not statistically significant. Among the six
completed trials of cortisol replacement in septic shock, only
two reported separate data according to the results of a
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Abstract
Based on several recently completed randomized controlled trials, cortisol replacement is likely to
become a standard of care for vasopressor dependent septic shock. Further studies are needed in
order to accomplish whether this treatment should be limited to patients with a blunted cortisol
response to corticotrophin. Similarly, in patients with severe sepsis who do not need vasopressors, the
benefit/risk ratio of cortisol replacement remains to be assessed.
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short corticotropin test [2,6], and only one trial was
adequately powered to assess the survival benefit of cortisol
replacement in patients with occult adrenal insufficiency [6].
In fact, in this trial, cortisol replacement dramatically improved
rates of survival for 28 days in the intensive care unit or
elsewhere in the hospital in the nonresponders to the ACTH
test but not in those having an increase in cortisol levels of
more than 9 µg/dl after ACTH. However, this trial was not
adequately powered to allow definite conclusions regarding
patients deemed to have normal cortisol response to ACTH
and we therefore need to wait for the results of the
CORTICUS study. In the meantime, cortisol replacement
should be considered only in vasopressor-dependent septic
shock with occult adrenal insufficiency. As the results of the
ACTH test might not be available everywhere at all times, it is
recommended that cortisol replacement be started
immediately after the ACTH test is performed, and that in the
light of the results of the test, treatment could be continued
for up to 7 days in nonresponders and stopped in patients
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Table 1
Recently completed randomized, controlled trials of cortisol replacement in septic shock
Study Methods Participants Interventions Outcome Comments
Bollaert et al.,  Randomized, two- N = 41, adults only Hydrocortisone, 300 mg per day  Shock reversal,  Improved time to 
1998 [2] center, double blind,  Vasopressor-dependent  (100 mg i.v. bolus) for 5 days and  death,  shock reversal in 
parallel groups septic shock then either stopped (if no effect on  complications 28-day survival
shock reversal) or progressively  No increase in 
tapered; or placebo complication rates
Briegel et al.,  Randomized,  N = 40, adults only Hydrocortisone, loading dose of  Shock reversal,  Improved time to 
1999 [3] monocenter, double  Vasopressor-dependent  100 mg in 30 min followed by  organ dysfunction,  shock reversal in 
blind, parallel groups septic shock continuous infusion 0.18 mg/kg  death organ dysfunction 
per h for 6 days and then  free-days
progressively tapered in steps of  No increase in 
24 mg/day; or placebo complication rates
Chawla et al.,  Randomized,  N = 41, adults only Hydrocortisone, 300 mg per day  Shock reversal,  Improved time to 
1999 [4] monocenter, double  Vasopressor-dependent  (100 mg i.v. bolus) for 5 days and  death, complications shock reversal in 
blind, parallel groups septic shock then either stopped (if no effect  28-day survival
on shock reversal) or progressively  No increase in 
tapered; or placebo complication rates
Keh et al.,  Randomized,  N = 40, adults only Hydrocortisone, loading dose of  Systemic  Improvement in 
1999 [5] placebo-controlled,  Vasopressor-dependent  100 mg in 30 min followed by  inflammation,  systemic 
monocenter, double  septic shock continuous infusion 0.18 mg/kg  systemic and  inflammation, 
blind, crossover per hour for 3 days; or placebo pulmonary  hemodynamics, and 
hemodynamics, vasopressor 
vasopressor requirements
requirement,  No increase in 
complications complication rates
Annane,  Randomized,  N = 300, adults only Hydrocortisone 200 mg/day  28-day survival,  Improvement in 
2000 [6]  placebo-controlled,  Vasopressor-dependent  (50 mg i.v. bolus) + fludrocortisone  shock reversal,  shock reversal and 
multicenter, double  and ventilator- 50 µg/day (oral) for 7 days or their  organ dysfunction  mortality
blind, parallel groups dependent septic shock respective placebo reversal,  No increase in 
complications complication rates